Cytokinetics and Pfizer announced strong US sales growth for Camzyos and a co-development agreement for Eliquis.
1 report, 1 independent
Updated Aug 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cytokinetics and Pfizer announced strong US sales growth for Camzyos and a co-development agreement for Eliquis.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Market growth is being driven by advanced therapies involving Pfizer, Novartis, and Merck.Also in this story
- Pfizer, Novartis, Merck, and Intravacc are competing in the high-cost gene therapy market, utilizing specialized manufacturing and vaccine production services.
- Pfizer and Novartis are notable market players in epilepsy therapeutics.
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Cytokinetics
company in South San Francisco, United States
Coverage
Newest first; wire copies grouped- ZacksWill Camzyos Strengthen BMY's Cardiovascular Portfolio? Bristol Myers’ (BMY) cardiovascular portfolio currently comprises blockbuster drugs Eliquis and Camzyos. Blood thinner medicine Eliquis, for wh